Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Albertsons Companies Inc (ACI) vs Amgen, Inc. (AMGN) Price & Performance

Albertsons Companies IncTrade
Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

Albertsons Companies Inc vs Amgen, Inc. — how do they compare? Albertsons Companies Inc trades at $12.25 (market cap $5.95B), while Amgen, Inc. trades at $414.3 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 37.7× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (5.55%). Which is the better fit depends on your goals.

ACIAMGN
Market Cap
$5.95B$224.14B
Sector
Consumer StaplesHealth
52-Week High
$19.74$417.20
52-Week Low
$11.03$271.18
Enterprise Value
$21.35B$267.45B
Dividend Yield
5.55%2.43%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Albertsons Companies Inc

Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.

Read more on ACI

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN